RARE vs SMMT · rev $350.0M vs $11.46B cap
Ultragenyx (RARE) versus Summit Therapeutics PLC (SMMT) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Summit Therapeutics PLC (SMMT) is a biotechnology company listed on US.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
SMMT does not have a complete income-statement cache yet.
RARE currently screens at market cap $2.79B. SMMT currently screens at market cap $11.46B.
Not investment advice. Open the RARE and SMMT stock pages for the full models.
Not investment advice.